Deraphan© is the combination of two clinically validated products, acting on well documented pharmacological pathways in the field of neuropsychiatry. Deraphan© shows the unique potential to address, both the neurological and psychological aspects of BPSD.

Dextromethorphan is a well established antitussive medication. Dextromethorphan has multiple mechanisms of action including NMDA receptor channel blockade. In recent years, the CNS properties of dextromethorphan have been demonstrated in the clinic, providing the adjunction of a CYP2D6 inhibitor to limit its metabolism.

EXV-801 is a selective serotonin (5-HT)2A/2C receptor inverse agonist that was developed in the clinic for the treatment of generalized anxiety disorder. This pharmacological pathway has been well documented to overcome a number of neuropsychiatric symptoms, such as hallucinations, insomnia, appetite disturbances, apathy, and anxiety. In addition, EXV-801 also inhibits CYP2D6.